Opendata, web and dolomites

denovoSkin SIGNED

Personalized, bio-engineered skin grafts for the permanent treatment of skin defects

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 denovoSkin project word cloud

Explore the words cloud of the denovoSkin project. It provides you a very rough idea of what is the project "denovoSkin" about.

clinical    sound    burden    considerably    avoids    economic    risking    5m    automate    bio    function    restore    reduce    16    57m    fast    rehabilitation    life    sme    homecare    starting    structure    dermo    intense    outstanding    painful    scars    entire    site    corrective    medical    wounds    interventions    intervention    patented    autologous    personalized    donor    suffer    autografting    considerable    fits    transplantation    psychosocial    fda    granted    world    atmp    health    orphan    swissmedic    significantly    global    17    human    leads    patients    50m    optimal    plan    deployment    denovoskin    investment    financial    surgical    de    instrument    leaves    follow    care    biopsy    quality    debilitating    engineered    movement    worldwide    market    patient    classified    disfiguring    burns    minimal    designation    issue    off    hence    quantities    stamp    shortage    impair    epidermal    performance    trade    last    logistics    assuring    therapy    standard    savings    surgeries    solving    permanent    skin    scarrring    sized    projected    treatment    every    graft    excision    ema    drug    defects    invested   

Project "denovoSkin" data sheet

The following table provides information about the project.

Coordinator
CUTISS AG 

Organization address
address: WEINBERGSTRASSE 35 WYSS TRANSLATIONAL CENTER ZURICH DENOVOS
city: ZURICH
postcode: 8006
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Switzerland [CH]
 Project website https://cutiss.swiss/
 Total cost 3˙571˙237 €
 EC max contribution 2˙499˙866 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-2
 Funding Scheme SME-2
 Starting year 2018
 Duration (year-month-day) from 2018-10-01   to  2020-09-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    CUTISS AG CH (ZURICH) coordinator 2˙499˙866.00

Map

 Project objective

Every year in the world, more than 50M patients suffer from skin defects (e.g. burns, excision, etc.) and need surgical intervention to restore skin function. Standard of care, skin autografting, very often leaves these patients with scars. Scars are permanent and disfiguring, and can also be painful and highly debilitating. Indeed, they may also impair movement and growth, and require several follow-up surgeries, intense homecare and psychosocial rehabilitation. Hence, scars significantly affect patient’s quality of life, along with the economic burden for the health-care system. Furthermore, in the case of large wounds, donor site shortage represents a real clinical issue.

denovoSkin™ is a patented, personalized, autologous bio-engineered human skin graft classified as Advanced Therapy Medical Product (ATMP). It is engineered in large quantities starting-off from a stamp-sized skin biopsy of the patient, thus solving the donor site shortage issue. Moreover, because of its dermo-epidermal structure, denovoSkin™ leads to minimal scarrring after transplantation. Its outstanding performance could considerably reduce or even avoids further corrective interventions, allowing for considerable savings in terms of costs. denovoSkin™ is also granted with Orphan Drug Designation for the treatment of burns by Swissmedic, EMA and FDA.

So far, more than €17.5M have been invested over the last 16 years of research into the development and the clinical testing of denovoSkin™. To have denovoSkin™ fully projected at a European and global level we need a further investment of €3.57M to automate its production, de-risking the entire denovoSkin™ project by assuring a real delivery to patients worldwide while providing optimal logistics and quality of product.

The proposed work in Phase 2 of the SME instrument fits into our overall plan to reach the market by contributing the financial resources needed to plan a fast sound wider deployment of denovoSkin™ and its market uptake.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "DENOVOSKIN" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "DENOVOSKIN" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

COPI (2020)

Carbon Offset Plug-in

Read More  

LIVELMIA (2019)

Innovative assay for microRNAs analysis

Read More  

Magnesys (2019)

Efficient filtering of metallic impurities in food processing

Read More